share_log

BTIG Initiates Coverage On Theravance Biopharma With Buy Rating, Announces Price Target of $21

Moomoo 24/7 ·  Apr 12 07:42

BTIG analyst Julian Harrison initiates coverage on Theravance Biopharma (NASDAQ:TBPH) with a Buy rating and announces Price Target of $21.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment